The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-6041-3806en_US
dc.contributor.authorBulur, Isil
dc.contributor.authorBaskan, Emel Bulbul
dc.contributor.authorOzdemir, Mustafa
dc.contributor.authorBalevi, Ali
dc.contributor.authorGoncu, Emek Kocaturk
dc.contributor.authorAltunay, Ilknur
dc.contributor.authorGonul, Muzeyyen
dc.contributor.authorErgin, Can
dc.contributor.authorErtam, Ilgen
dc.contributor.authorErdogan, Hilal Kaya
dc.contributor.authorBilgin, Muzaffer
dc.contributor.authorErdem, Mustafa Teoman
dc.date.accessioned2024-07-12T21:44:16Z
dc.date.available2024-07-12T21:44:16Z
dc.date.issued2018en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractIntroduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H-1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS(7)) after omalizumab treatment improved significantly compared to the pretreatment score (p < 0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab's treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 +/- 6.15 before treatment and decreased to 3.55 +/- 3.60 6 months after treatment (p < 0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS(7) decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data.en_US
dc.identifier.doi10.15570/actaapa.2018.25
dc.identifier.endpage126en_US
dc.identifier.issn1318-4458
dc.identifier.issn1581-2979
dc.identifier.issue3en_US
dc.identifier.pmid30244261en_US
dc.identifier.scopus2-s2.0-85055208666en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage121en_US
dc.identifier.urihttps://dx.doi.org/10.15570/actaapa.2018.25
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7705
dc.identifier.volume27en_US
dc.identifier.wosWOS:000445819800002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherDERMATOVENEROLOGICAL SOC SLOVENIAen_US
dc.relation.ispartofACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY00041
dc.subjectchronic spontaneous urticariaen_US
dc.subjectomalizumaben_US
dc.subjectdermatology life qualityen_US
dc.subjectUAS(7)en_US
dc.subjectside effectsen_US
dc.titleThe efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkeyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu